Latest Coya Therapeutics News & Updates

See the latest news and media coverage for Coya Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

Coya Therapeutics

Clinical-stage biotech developing Treg therapies

coyatherapeutics.com

Headquarters: Houston, United States
Founded year: 2020
Company type: Private company
Number of employees: 2–20

Last updated Today

Latest news about Coya Therapeutics

In short: Coya Therapeutics advanced its clinical pipeline, securing FDA Fast Track status and IND acceptances for COYA 302 in ALS and frontotemporal dementia.

Company announcements

June 8 Coya Therapeutics

Coya announces first ALSTARS trial extension cohort

Patients completing the placebo phase now receive COYA 302 in the blinded extension.

May 22 Coya Therapeutics

Coya Therapeutics receives FDA Fast Track for COYA 302

The designation highlights urgent unmet need in ALS and advances ongoing Phase 2 ALSTARS trial.

May 12 Coya Therapeutics

Coya Therapeutics reports first quarter 2026 financial results

The company highlights FDA Fast Track for COYA 302 in ALS and progress in the ALSTARS trial.

April 22 Coya Therapeutics

Coya Therapeutics announces biomarker study publication

The study shows correlations between oxidative stress, inflammation, neuronal injury biomarkers and ALS progression. Findings support COYA 302's rationale.

Media coverage

June 11 The Globe and Mail

Coya Therapeutics Establishes $30 Million ATM Equity Program

Detailed price information for Coya Therapeutics Inc (COYA-Q) from The Globe and Mail including charting and trades.

June 10 NeurologyLive

Phase 3 Data Levacetylleucine Data in Niemann-Pick, FDA Requests Data for Deramiocel to Fulfill Submission, COYA 302 and Frontotemporal Dementia | NeurologyLive - Clinical Neurology News and Neurology Expert Insights

Recently announced data from a small-scale, investigator-initiated trial showed that treatment with COYA 302 (Coya Therapeutics), a combination of low-dose interleukin-2 (IL2) plus CTLA-4 Ig...

June 8 Yahoo Finance

Coya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-Treatment Extension Phase

Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces the initiation of the...

May 27 NeurologyLive

COYA 302 Heads to Phase 2 Trial of ALS Following IND Acceptance | NeurologyLive - Clinical Neurology News and Neurology Expert Insights

According to a recent announcement, the FDA has accepted the investigational new drug application (IND) for COYA 302 (Coya Therapeutics), a proprietary combination therapy of...

Never miss news about Coya Therapeutics

Track Coya Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.